A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.
Chagas disease or American trypanosomiasis, caused by Trypanosoma cruzi, affects about 18 million people living mostly in Latin America. The parasite is transmitted to humans by blood-sucking reduviid bugs, also known as kissing bugs due to their predilection for feeding on the faces of their victims. In the United States, Chagas disease is considered one of the neglected parasitic infections, a group of five parasitic diseases that have been targeted by CDC for public health action.
"While historically infection was largely confined to poor and rural populations in Central and South America, it has been emerging in the U.S., Canada, Europe, Japan, and Australia, due to immigration, and nonvectorial transmission is becoming a public health threat," says Deborah Nicoll-Griffith of the Merck Frosst Centre for Therapeutic Research in Kirkland, Quebec, a researcher on the study. One 2005 estimate put the number of people infected within the U.S. at 300,000 (1/1000).
There are two phases of Chagas disease: the acute phase and the chronic phase. Both phases can be symptom free or life threatening. Left untreated the disease can lead to cardiac and digestive disorders, as the parasite burrows into the heart, esophagus and colon tissue where it causes damage over time.
The current standard of care, the drug benznidazole, has significant activity against the parasite during the acute phase, but is less effective once the disease becomes chronic.
Efforts to find new drugs focus on disrupting an enzyme, cruzipain, which the parasite uses for digestion, to produce other cellular machinery, to evade the host's immune system, and to invade heart and gastrointestinal tissues.
Nicoll-Griffith and her colleagues identified two compounds known as reversible cysteine protease inhibitors that fit cruzipain like jigsaw puzzle pieces, jamming the enzyme. In the study, they tested the efficacy of the compounds in mice against that of benznidazole. While all treatment groups showed a marked reduction in parasite burden, in all tissues, the two experimental compounds had greater cure rates of acute infections (90% and 78%) compared to benznidazole (71%.)
"The efficacy shown in these T. cruzi murine studies suggests that nitrile-containing cruzipain inhibitors show promise as a viable approach for a safe and effective treatment of Chagas disease," write the researchers.
Explore further: Cure in sight for kissing bug's bite
More information: www.asm.org/images/Communications/tips/2013/1213chagas.pdf
Medical Xpress on facebook
Related Stories
Cure in sight for kissing bug's bite
Feb 14, 2013
Chagas disease, a deadly tropical infection caused by the protozoan parasite Trypanosoma cruzi and transmitted by biting insects called "kissing bugs," has begun to spread around the world, including the U.S. Yet current treatm ...
Drug trial for top parasitic killer of the Americas: Mixed results, new evidence to improve therapy
Nov 14, 2013
According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing ...
300,000 people in U.S. living with Chagas disease: report
Jul 05, 2012
(HealthDay) -- As many as 300,000 people in the United States may have chronic Chagas disease -- mostly spread by blood-sucking insects -- health officials report.
Leading cause of heart disease ignored in North America's poorest communities
Oct 31, 2013
A leading cause of heart disease remains overlooked in North America's most impoverished communities, researchers said today in an editorial published in PLOS Neglected Tropical Diseases. Chagas disease has rendered a heav ...
Researchers to develop new diagnostic test for Chagas disease
Nov 22, 2012
(Medical Xpress)—Researchers at the University of Georgia will soon begin a study designed to identify new ways of determining treatment efficacy in Chagas disease, a potentially fatal tropical disease ...
Recommended for you
New MERS death raises Saudi toll to 57
6 minutes ago
Saudi health authorities announced Thursday a new MERS death, bringing to 57 the number of people killed by the coronavirus in the country with the most fatalities.
Hong Kong reports first H7N9 death
5 hours ago
A Hong Kong man infected with the H7N9 strain of bird flu died on Thursday, the first such death in the city since the virus emerged there this month.
Adding cognitive behavioral therapy to treatment of pediatric migraine improves relief of symptoms
Dec 24, 2013
Among children and adolescents with chronic migraine, the use of cognitive behavioral therapy (CBT) resulted in greater reductions in headache frequency and migraine-related disability compared with headache education, according ...
Use of antidepressant does not improve symptoms from stomach disorder
Dec 24, 2013
Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing ...
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
Dec 24, 2013
A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced ...
Genetic clue to fighting new strains of flu
Dec 24, 2013
(Medical Xpress)—Researchers at the University of Melbourne have discovered a genetic marker that can accurately predict which patients will experience more severe disease in a new strain of influenza (H7N9) ...
User comments
© Medical Xpress 2011-2013, Science X network
A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.
Chagas disease or American trypanosomiasis, caused by Trypanosoma cruzi, affects about 18 million people living mostly in Latin America. The parasite is transmitted to humans by blood-sucking reduviid bugs, also known as kissing bugs due to their predilection for feeding on the faces of their victims. In the United States, Chagas disease is considered one of the neglected parasitic infections, a group of five parasitic diseases that have been targeted by CDC for public health action.
"While historically infection was largely confined to poor and rural populations in Central and South America, it has been emerging in the U.S., Canada, Europe, Japan, and Australia, due to immigration, and nonvectorial transmission is becoming a public health threat," says Deborah Nicoll-Griffith of the Merck Frosst Centre for Therapeutic Research in Kirkland, Quebec, a researcher on the study. One 2005 estimate put the number of people infected within the U.S. at 300,000 (1/1000).
There are two phases of Chagas disease: the acute phase and the chronic phase. Both phases can be symptom free or life threatening. Left untreated the disease can lead to cardiac and digestive disorders, as the parasite burrows into the heart, esophagus and colon tissue where it causes damage over time.
The current standard of care, the drug benznidazole, has significant activity against the parasite during the acute phase, but is less effective once the disease becomes chronic.
Efforts to find new drugs focus on disrupting an enzyme, cruzipain, which the parasite uses for digestion, to produce other cellular machinery, to evade the host's immune system, and to invade heart and gastrointestinal tissues.
Nicoll-Griffith and her colleagues identified two compounds known as reversible cysteine protease inhibitors that fit cruzipain like jigsaw puzzle pieces, jamming the enzyme. In the study, they tested the efficacy of the compounds in mice against that of benznidazole. While all treatment groups showed a marked reduction in parasite burden, in all tissues, the two experimental compounds had greater cure rates of acute infections (90% and 78%) compared to benznidazole (71%.)
"The efficacy shown in these T. cruzi murine studies suggests that nitrile-containing cruzipain inhibitors show promise as a viable approach for a safe and effective treatment of Chagas disease," write the researchers.
Explore further: Cure in sight for kissing bug's bite
More information: www.asm.org/images/Communications/tips/2013/1213chagas.pdf
Medical Xpress on facebook
Related Stories
Cure in sight for kissing bug's bite
Feb 14, 2013
Chagas disease, a deadly tropical infection caused by the protozoan parasite Trypanosoma cruzi and transmitted by biting insects called "kissing bugs," has begun to spread around the world, including the U.S. Yet current treatm ...
Drug trial for top parasitic killer of the Americas: Mixed results, new evidence to improve therapy
Nov 14, 2013
According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing ...
300,000 people in U.S. living with Chagas disease: report
Jul 05, 2012
(HealthDay) -- As many as 300,000 people in the United States may have chronic Chagas disease -- mostly spread by blood-sucking insects -- health officials report.
Leading cause of heart disease ignored in North America's poorest communities
Oct 31, 2013
A leading cause of heart disease remains overlooked in North America's most impoverished communities, researchers said today in an editorial published in PLOS Neglected Tropical Diseases. Chagas disease has rendered a heav ...
Researchers to develop new diagnostic test for Chagas disease
Nov 22, 2012
(Medical Xpress)—Researchers at the University of Georgia will soon begin a study designed to identify new ways of determining treatment efficacy in Chagas disease, a potentially fatal tropical disease ...
Recommended for you
New MERS death raises Saudi toll to 57
6 minutes ago
Saudi health authorities announced Thursday a new MERS death, bringing to 57 the number of people killed by the coronavirus in the country with the most fatalities.
Hong Kong reports first H7N9 death
5 hours ago
A Hong Kong man infected with the H7N9 strain of bird flu died on Thursday, the first such death in the city since the virus emerged there this month.
Adding cognitive behavioral therapy to treatment of pediatric migraine improves relief of symptoms
Dec 24, 2013
Among children and adolescents with chronic migraine, the use of cognitive behavioral therapy (CBT) resulted in greater reductions in headache frequency and migraine-related disability compared with headache education, according ...
Use of antidepressant does not improve symptoms from stomach disorder
Dec 24, 2013
Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing ...
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
Dec 24, 2013
A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced ...
Genetic clue to fighting new strains of flu
Dec 24, 2013
(Medical Xpress)—Researchers at the University of Melbourne have discovered a genetic marker that can accurately predict which patients will experience more severe disease in a new strain of influenza (H7N9) ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment